Viatris (VTRS) Cash from Investing Activities (2019 - 2026)
Viatris (VTRS) posted Cash from Investing Activities of -$51.6 million for Q2 2026, down 118.6% on a QoQ basis from $277.4 million in Q1 2026, and up 1.71% year-over-year from -$50.7 million in Q2 2025.
Analysis
Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Viatris has reported Cash from Investing Activities for 8 years, with the latest figure at -$51.6 million in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 1.71% year-over-year to -$51.6 million in Q2 2026; TTM through Jun 2026 was -$84.3 million, a 105.77% decrease from a year earlier, with the FY2025 full-year figure at -$427.7 million, down 123.75% from the prior year.
- Cash from Investing Activities was -$51.6 million for Q2 2026 at Viatris, down from $277.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2024, with the low at -$749.5 million in Q1 2023.
- Average Cash from Investing Activities over 5 years is $122.7 million, with a median of -$66.0 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 1020.33% in 2023, then jumped 3283.79% in 2024.
- Over 5 years, Cash from Investing Activities stood at $1.7 billion in 2022, then plunged by 98.46% to $26.7 million in 2023, then slumped by 731.84% to -$168.7 million in 2024, then retreated by 25.19% to -$211.2 million in 2025, then jumped by 75.57% to -$51.6 million in 2026.
- The last three Cash from Investing Activities figures came in at -$51.6 million (Q2 2026), $277.4 million (Q1 2026), and -$211.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -491.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -51.60 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 40.52 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -122.74 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | -93.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -44.77 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | -3.05 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 44.87 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.60 Mn |
| Mar 31, 2026 | 277.40 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 375.80 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Dec 31, 2023 | 26.70 Mn |
| Sep 30, 2023 | -54.90 Mn |
| Jun 30, 2023 | -86.80 Mn |
| Mar 31, 2023 | -749.50 Mn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | -115.00 Mn |
| Jun 30, 2022 | -82.10 Mn |
| Mar 31, 2022 | -66.90 Mn |
| Dec 31, 2021 | -219.10 Mn |
| Sep 30, 2021 | -118.20 Mn |